Provided by Tiger Trade Technology Pte. Ltd.

Legend Biotech

18.64
-0.5500-2.87%
Post-market: 18.850.2100+1.13%19:38 EDT
Volume:4.28M
Turnover:80.23M
Market Cap:3.63B
PE:-37.22
High:19.85
Open:19.48
Low:18.61
Close:19.19
52wk High:37.50
52wk Low:16.24
Shares:194.49M
Float Shares:91.34M
Volume Ratio:3.10
T/O Rate:4.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5008
EPS(LYR):-1.6200
ROE:-8.08%
ROA:-1.92%
PB:2.95
PE(LYR):-11.51

Loading ...

Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate

Benzinga Earnings
·
Aug 11

Legend Biotech Corporation - Carvykti Net Trade Sales Increase 50% in Q2 2026 to $657 Mln

THOMSON REUTERS
·
Aug 11

Legend Biotech Corporation Q2 Adjusted EPS USD 0.16 VS. Ibes Estimate USD 0.07

THOMSON REUTERS
·
Aug 11

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

THOMSON REUTERS
·
Aug 11

After Multiple Bearish Catalysts, Legend Biotech's Stock Halved in Two Months: Value Trap or Bargain Opportunity?

Stock News
·
Aug 11

Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets

Dow Jones
·
Aug 11

Legend Biotech Corporation Expected to Post Earnings of 7 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Earning Preview: Legend Biotech this quarter’s revenue is expected to increase by 55.36%, and institutional views are positive

Earnings Agent
·
Aug 05

Legend Biotech Interim CEO Alan Bash Files Initial Beneficial Ownership Statement

Reuters
·
Aug 04

Legend Biotech (LEGN) CEO Exit Raises Questions, Is The Stock Still Cheap?

Simply Wall St.
·
Jul 31

Legend Biotech to Host Investor Call on Second-quarter 2026 Results

Reuters
·
Jul 28

Legend Biotech Corp : Raymond James Cuts Target Price to $58 from $86

THOMSON REUTERS
·
Jul 28

Legend Biotech Price Target Maintained with a $65.00/Share by HC Wainwright & Co.

Dow Jones
·
Jul 28

Buy Rating Reiterated as Strong CARVYKTI Momentum and Attractive Valuation Support Unchanged $65 Price Target

TIPRANKS
·
Jul 28

Under the Radar: Legend Stock Tumbles After CEO's Abrupt Departure

Dow Jones
·
Jul 28

Legend Biotech's In Vivo CAR-T Cell Therapy Data Validates Approach, RBC Capital Markets Says

MT Newswires Live
·
Jul 27

Legend Biotech is Maintained at Outperform by RBC Capital

Dow Jones
·
Jul 27

Legend Biotech falls -12.5%

TIPRANKS
·
Jul 27

Legend Biotech price target lowered to $59 from $63 at RBC Capital

TIPRANKS
·
Jul 27

RBC Cuts Price Target on Legend Biotech to $59 From $63, Keeps Outperform Rating

MT Newswires Live
·
Jul 27